Compare Incyte Corporation (INCY) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NetEase Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while NetEase Inc trades at $130.59 (market cap $86.14B). The key difference: NetEase Inc is far larger — about 3.7× Incyte Corporation's market cap, and NetEase Inc pays a 2.25% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NTES | |
|---|---|---|
Market Cap | $23.11B | $86.14B |
Sector | Health | Media |
52-Week High | $118.52 | $159.34 |
52-Week Low | $67.38 | $109.26 |
Enterprise Value | $19.13B | $62.61B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NetEase (NTES) trades at $134.20, up 2.22% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.53, and maintains robust profitability with a net income margin near 30%. Recent news highlights international expansion and positive analyst sentiment, with a dividend of $0.72 paid in June 2026.
Outlook remains positive driven by earnings growth and international gaming titles, but risks include China market volatility and competitive pressures. Wall Street consensus is strongly bullish with 82% buy ratings, suggesting potential upside from current levels amid solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
